Deaton; David Norman
Patent Applications and Registrations
Patent applications and USPTO patent grants for Deaton; David Norman.The latest application filed is for "chemical compounds".
- Deaton; David Norman - Collegeville PA
- DEATON; David Norman - King of Prussia PA
- Deaton; David Norman - Durham NC
- Deaton; David Norman - Raleigh NC
- DEATON, DAVID NORMAN - RESEARCH TRIANGLE PARK NC
- Deaton; David Norman - Cary NC
| Patent | Date |
|---|---|
| Chemical Compounds App 20220009918 - Cadilla; Rodolfo ; et al. | 2022-01-13 |
| Chemical compounds as H--PGDS inhibitors Grant 11,149,035 - Deaton , et al. October 19, 2 | 2021-10-19 |
| Chemical Compounds App 20210238162 - CADILLA; Rodolfo ; et al. | 2021-08-05 |
| 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors Grant 11,053,234 - Deaton , et al. July 6, 2 | 2021-07-06 |
| Fused Pyridines Which Act As Inhibitors Of H Pgds App 20210139507 - DEATON; David Norman ; et al. | 2021-05-13 |
| Chemical Compounds as H-PGDS Inhibitors App 20200123152 - DEATON; David Norman ; et al. | 2020-04-23 |
| 1,3 Di-substituted Cyclobutane Or Azetidine Derivatives As Hematopoietic Prostaglandin D Synthase Inhibitors App 20190241554 - DEATON; David Norman ; et al. | 2019-08-08 |
| CD38 inhibitors and methods of treatment Grant 9,840,496 - Becherer , et al. December 12, 2 | 2017-12-12 |
| Cd38 Inhibitors And Methods Of Treatment App 20170260164 - BECHERER; J. David ; et al. | 2017-09-14 |
| Farnesoid X receptor agonists Grant 8,158,665 - Caldwell , et al. April 17, 2 | 2012-04-17 |
| Farnesoid X receptor agonists Grant 7,960,552 - Bass, III , et al. June 14, 2 | 2011-06-14 |
| Farnesoid X Receptor Agonists App 20110034507 - Akwabi-Ameyaw; Adwoa ; et al. | 2011-02-10 |
| Farnesoid X Receptor Agonists App 20100249179 - Deaton; David Norman ; et al. | 2010-09-30 |
| Farnesoid X Receptor Agonists App 20100160398 - Caldwell; Richard ; et al. | 2010-06-24 |
| Farnesoid X Receptor Agonists App 20100120775 - Bass, III; Jonathan York ; et al. | 2010-05-13 |
| Farnesoid X receptor agonists Grant 7,705,028 - Caldwell , et al. April 27, 2 | 2010-04-27 |
| Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss Grant 7,402,606 - Barrett , et al. July 22, 2 | 2008-07-22 |
| Farnesoid X Receptor Agonists App 20080167356 - CALDWELL; Richard ; et al. | 2008-07-10 |
| Cycloalkyl Ketoamides Derivatives Useful As Cathepsin K Inhibitors App 20080058333 - Catalano; John George ; et al. | 2008-03-06 |
| Propylcarbamate derivatives as inhibitors of serine and cysteine proteases Grant 7,288,541 - Deaton , et al. October 30, 2 | 2007-10-30 |
| Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors Grant 7,282,512 - Catalano , et al. October 16, 2 | 2007-10-16 |
| Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss App 20050245596 - Barrett, David Gene ; et al. | 2005-11-03 |
| Alpha-ketoamide derivatives as cathepsin k inhibitors App 20050107616 - Barrett, David Gene ; et al. | 2005-05-19 |
| Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors App 20050054819 - Catalano, John George ; et al. | 2005-03-10 |
| Propylcarbamate derivatives as inhibitors of serine and cysteine proteases App 20050043368 - Deaton, David Norman ; et al. | 2005-02-24 |
| Benzimidazole Derivatives App 20020094963 - DRACH, JOHN CHARLES ; et al. | 2002-07-18 |
| Formamides as therapeutic agents Grant 6,172,064 - Andrews , et al. January 9, 2 | 2001-01-09 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 